032346AF5
Amylin Pharmaceuticals, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that developed injectable diabetes medicines. Its flagship product, Byetta (exenatide), was one of the first widely used GLP-1 receptor agonist treatments for type 2 diabetes, while Symlin (pramlintide) targeted the hormone amylin to help control blood sugar after meals. Founded in 1987 in San Diego, the company took its name from that same hormone — amylin, the protein its scientists set out to study and mimic. Bristol-Myers Squibb acquired Amylin in 2012.
NOTEUnderlying: AMLNCUSIP: 032346AF5HealthcareUS1 derivative reporter
3.000% Note due 06/15/2014
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
